Welcome to ViraTherapeutics
Viruses designed for cancer therapy
ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients in 2018 at the earliest.
Press release - May 30, 2017
ViraTherapeutics appoints Heinz Schwer as CEO
20170530_PR-ViraT-CEO_ENG_final.pdf
PDF-Dokument [73.3 KB]
20170530_PR-ViraT-CEO_GER_final.pdf
PDF-Dokument [75.3 KB]
“I am very happy that we could attract Dr. Schwer to join ViraTherapeutics as CEO. Fueled by our strong R&D partnership with Boehringer Ingelheim, ViraTherapeutics is transitioning from a pre- clinical stage company to a clinical stage company. We are convinced that Dr. Schwer, with his experience and track record, is the right person to lead ViraTherapeutics into the future,” said Dr. Klaus Schollmeier, chairman of the supervisory board of ViraTherapeutics.
Druckversion